Bioequivalence Study of Two Extended Release Formulations Containing 50 mg of Quetiapine.

Inclusion Criteria: * Signed informed consent. * Healthy volunteers according to medical history, physical exam, clinical laboratory, chest X-rays and ECG. * Gender: males and non pregnant females * Age: 18 to 55 years. * Body mass index: 19 to 27 kg/m\^2. Exclusion Criteria: * History of liver or renal disease, or psychiatric disorders. * History of drug or alcohol abuse during the previous two years. * Smokers of more than 10 cigarrettes a day. * Any kind of medicines taken during the previous two weeks. * Any history of disease or disorders clinically significant according to the Principal Investigator. * Abnormal ECG. * Abnormal chest X-ray. * Hypersensitivity to quetiapine or excipients within the formulations. * Positive diagnostic test for HIV or hepatitis A, B or C virus. * Breast feeding females. * Positive beta-HCG test. * Positive drug test in urine. * Participation in clinical trials in the previous three months. * Blood donation in the previous three months. * Clinically significant laboratory results. * Subjects seeking to initiate any medical or pharmacological treatment. * Subjects unwilling to keep fasting or diet indications. * Uncooperative subjects.